This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The development of vaccines for SARS-CoV-2 becomes more difficult due to the viral mutation in its non-structural proteins (NSPs) especially NSP2 and NSP3, S protein, and RNA-dependent RNA polymerase (RdRp).
Forging the toolkit for subcellular omics Cellular components known as organelles, consisting of RNA and protein, exert vital influences on human wellbeing and ailments by sustaining equilibrium, managing growth and ageing, and producing energy.
By Allessandra DiCorato June 18, 2024 Credit: Jon Arizti-Sanz SHINE, a rapid diagnostic test developed by Pardis Sabeti's lab in 2020, uses paper strips and CRISPR enzymes to identify specific sequences of viral RNA in samples. Then, in 2022, they began adapting the assay to detect other viruses they knew were always circulating: influenzas.
This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).
The method, called Genotypic and Phenotypic Antibiotic Susceptibility Testing through RNA detection, or GoPhAST-R, analyzes the growth and genetic activity of the bacteria to quickly determine the pathogen’s susceptibility to various medicines.
But some species control genetic responses another way – via RNA editing. In a new report in Cell , Joshua Rosenthal of the Marine Biological Laboratory at Woods’ Hole and Eli Eisenberg at Tel Aviv University describe how the cephalopods – octopi, squid, and cuttlefish – change mRNAs in ways that alter enzymes.
Now researchers at the Broad Institute of MIT and Harvard have used cutting-edge continuous laboratory evolution and engineering methods to develop improved versions of the gene-editing tool. Reverse transcriptase proteins that copy RNA templates into strands of DNA are found naturally in all plant and animal cells and in many viruses.
What is special about these synthetically designed elements is that they show remarkable specificity to the target cell type they were designed for," said Ryan Tewhey, an associate professor at The Jackson Laboratory and co-senior author of the work with Steven Reilly of Yale, and Pardis Sabeti of the Broad.
William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines The groundbreaking, scalable technology is widely used in laboratories around the world today to efficiently produce large amounts of protein and RNA. Merkin (left) and F.
Although this ancestral replicase appears to have been lost, key aspects of RNA-catalyzed RNA replication can be studied by proxy with the use of modern RNA enzymes (ribozymes) generated by in vitro evolution.
The method, called Genotypic and Phenotypic Antibiotic Susceptibility Testing through RNA detection, or GoPhAST-R, analyzes the growth and genetic activity of the bacteria to quickly determine the pathogen’s susceptibility to various medicines.
Jude Children’s Research Hospital have discovered that oleic acid, one of the most abundant fatty acids in the body, restores a healthy balance of vaginal microbes in a laboratory model of BV. Using RNA sequencing and working with the Broad’s Metabolomics Platform and collaborators at St.
Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. The novel, hairpin-shaped molecule was named cabRNA for CBASS-activating bacteriophage RNA.
Gene therapy requires DNA and/or RNA delivery and analysis, and while most ongoing research involves therapies being delivered in vivo via adeno-associated viral (AAV) vectors, other in vivo delivery methods are on the rise. This ability to analyze variation from limited samples has made genetic diagnosis easier than ever.
We can test their viability in the population, speeding up discovery and saving resources associated with laboratory target validation. 1 Targets were then further validated by combining testing the most promising drug candidates and knocking down specific targets using short interfering RNA (siRNA) and antisense oligonucleotides (ASOs).
Imaging Modalities Help Visualize and Confirm Findings An emerging method of studying viruses is by using high-content imaging solutions to visualize the activity of small interfering RNA (siRNA), also known as short interfering RNA or “silencing” RNA.
Each cultured 3D “organoid”—which sits comfortably in the bottom of a pea-sized well on a standard laboratory plate—comes complete with its very own neurons, support cells, blood vessels, and immune cells! The sequencing data reflect the genomic activity within the organoid following exposure to each of the 60 compounds.
In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Today, several companies have ATR inhibitors at various stages of clinical development, which to a significant extent was influenced by early works from the laboratory.
Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.
. “Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. Heinrich Jehle, managing director of 3a-Diagnostics. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA.
The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. If successful, molnupiravir could help address the continued urgent need for therapeutics.”. About Molnupiravir.
Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology. coli extract-based cell-free protein expression assays.
The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.
Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways. FLT3 mutations seen in acute myeloid leukemia (AML) and BCR-ABL1 fusion gene seen in chronic myeloid leukemia (CML) are two examples.
Adult laboratory mice heal injuries with scar tissue, but spiny mice have the unique ability to regrow lost skin and regenerate musculoskeletal tissues in their body. It also showed that increasing and maintaining this type of signalling in laboratory mice could initiate a regenerative response instead of scarring.
The new cells are then grown in high numbers in a laboratory and then are re-administered to the patient, where the genetically modified cells will attack more specific cancer cells. This technology extensively utilizes immunofluorescence and flow cytometry technology, which is a platform offered in our laboratories.
Flow cytometry and RNA sequencing analysis demonstrated these cells to be both cytotoxic and actively proliferating. Furthermore, RNA sequencing suggested that these cells may respond to the immune-related protein interferon, but more research is needed to confirm the significance.
Farruk Kabir | NGS Lab Manager | Aperture NextGen Laboratories Aperture NextGen Laboratories is an FDA approved CLIA lab for interdisciplinary clinical testing and research. "For the last couple of years, we've been Covid testing and have been very successful with the SPT Labtech liquid handlers."
In both studies, >98% of participants who initiated treatment with Biktarvy and remained in the study achieved and maintained an undetectable viral load (HIV-1 RNA <50 copies/mL) through four years of follow-up (n=235/237 for study 1489, n=241/243 for study 1490). If appropriate, anti-hepatitis B therapy may be warranted.
Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Accurate and timely laboratory diagnosis of COVID-19 is one of the most pivotal requirements for optimal disease management and contact tracing.
Point of care testing increases access to high quality diagnostics solutions for the detection of a current SARS-CoV-2 infection, regardless of laboratory testing infrastructure or patient mobility. This is highly beneficial where timely decisions are needed or laboratory testing is inaccessible.
Despite PRAC’s ongoing surveillance and review, no safety signal is being found for the low platelet and clotting syndrome with either of the two authorized messenger RNA (mRNA) vaccines. Currently, EMA is evaluating “the first batch of data” for sotrovimab, including laboratory and animal studies and quality-related data, said the agency.
Researchers were able to use our synthetic RNA controls as a reference to verify and validate assays. We were able to develop these rapidly to eliminate the need to grow COVID-19 in BSL-3 labs for the purpose of making a reference sample.
At the recent ISCT 2024 – Signature Series, researchers from Charles River Laboratories presented a study 1 to predict the optimal cell culture parameters using a ML model. How is AI being integrated into current cell and gene therapy manufacturing processes to enhance operational efficiency and accelerate treatment access?
Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors.
That’s not the case with RNA-targeted drugs. The Foundation also is working with contract research organizations to conduct limited preclinical studies, with Illumina and Covance for genomics data, and with Charles River Laboratories and the Korea Institute of Toxicology. “I
CENTOGENE’s SARS-CoV-2 test is a molecular diagnostic test performed for the in vitro qualitative detection of RNA from the SARS-CoV-2 in oropharyngeal samples from presymptomatic patients and probands according to the recommended testing by public health authority guidelines.
“Our decades-long commitment to fighting the epidemic is stronger than ever as we continue to build on our legacy of research and innovation in HIV,” said Dr. Joan Butterton, vice president, Global Clinical Development, Infectious Diseases, Merck Research Laboratories. “We If appropriate, initiation of anti-HBV therapy may be warranted.
” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response.
CTCs enable the complete picture of a cancer to be seen, as, being an intact cell, they allow DNA, RNA and protein analysis and thus provide comparable analysis to a tissue biopsy. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive).
Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services, has also been essential to the successful execution of the COVE study. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Nov.
Bright light engulfs the Cultivarium laboratory in Watertown, Massachusetts. Lee showed me around the laboratories on a clear day in April. While the laboratory itself wasn’t out of the ordinary, some of its contents were. Extremophiles streaked on agar plates in the Cultivarium laboratory. Photos by the author.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content